Key Details
Price
$51.66Last Dividend
$0.33Annual ROE
10.31%Beta
1.06Events Calendar
Next earnings date:
May 01, 2025Recent quarterly earnings:
Jan 29, 2025Recent annual earnings:
Aug 08, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 04, 2024Next split:
N/ARecent split:
Sept 29, 2000Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
AVT's second-quarter fiscal 2025 results highlight continued weakness in the Electronic Components and Farnell segments.
Avnet, Inc. (NASDAQ:AVT ) Q2 2025 Earnings Conference Call January 29, 2025 11:00 AM ET Company Participants Joseph Burke - Vice President, Treasurer & Investor Relations Philip Gallagher - Chief Executive Officer Ken Jacobson - Chief Financial Officer Conference Call Participants Toshiya Hari - Goldman Sachs William Stein - Truist Securities Joe Quatrochi - Wells Fargo Ruplu Bhattacharya - Bank of America Operator Welcome to the Avnet Second Quarter Fiscal Year 2025 Earnings Call. I would now like to turn the floor over to Joe Burke, Vice President Treasury and Investor Relations for Avnet.
Avnet (AVT) came out with quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $1.40 per share a year ago.
Although the revenue and EPS for Avnet (AVT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Avnet (AVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet to participate in investor conferences in December.
PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet declares regular quarterly dividend.
Examine Avnet's (AVT) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech's proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. This is believed to be the first marketing authorization application filing announced globally for a biosimilar candidate to Simponi. The approvals process is anticipated to be completed in the fourth quarter of 2025.
While the top- and bottom-line numbers for Avnet (AVT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
FAQ
- What is the primary business of Avnet?
- What is the ticker symbol for Avnet?
- Does Avnet pay dividends?
- What sector is Avnet in?
- What industry is Avnet in?
- What country is Avnet based in?
- When did Avnet go public?
- Is Avnet in the S&P 500?
- Is Avnet in the NASDAQ 100?
- Is Avnet in the Dow Jones?
- When was Avnet's last earnings report?
- When does Avnet report earnings?
- Should I buy Avnet stock now?